What is the recommended management for a 60-year-old woman with Hashimoto’s thyroiditis and rheumatoid arthritis on chronic steroids who presents with new-onset confusion, paranoia, and excessive drooling?

Immediate Steroid-Induced Neuropsychiatric Emergency

This 60-year-old woman on chronic steroids for rheumatoid arthritis and Hashimoto's thyroiditis presenting with new-onset confusion, paranoia, and excessive drooling most likely has steroid-induced psychosis, though Hashimoto's encephalopathy (steroid-responsive encephalopathy associated with autoimmune thyroiditis, SREAT) must be urgently excluded before any steroid adjustment.

Critical First Steps

Rule Out Hashimoto's Encephalopathy FIRST

• Obtain anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies immediately 1, 2, 3
• Check TSH, free T4, inflammatory markers (ESR/CRP)
• Brain MRI to exclude stroke, infection, or other structural pathology 1, 2
• If anti-TPO antibodies are markedly elevated (typically >1000 IU/mL) with negative infectious/metabolic workup, SREAT is the diagnosis 1, 2

Critical distinction: SREAT requires HIGH-DOSE steroids (methylprednisolone 1g IV daily × 3 days), while steroid-induced psychosis requires STOPPING steroids 2, 3. Getting this wrong is catastrophic.

Diagnostic Algorithm

If Anti-TPO Antibodies Are Markedly Elevated + Negative Workup = SREAT

Treatment: Methylprednisolone 1g IV daily × 3 days, then oral prednisone taper over 13 weeks 2, 3

• 94.1% of older patients respond favorably to steroids 3
• 56.8% return to near-baseline function, 29.4% show partial improvement 3
• Some patients respond to reduced dose (500mg/day × 3 days) with similar outcomes 3
• Consider IVIG if steroid-intolerant or incomplete response 1
• Novel option: efgartigimod-α (FcRn antagonist) 800mg for steroid-intolerant cases 4

If Anti-TPO Antibodies Normal or Mildly Elevated = Steroid-Induced Psychosis

Treatment: Rapid steroid taper while managing psychosis 5, 6, 7

• High-dose glucocorticoids cause neuropsychiatric disorders including psychosis 5
• Taper steroids as rapidly as clinically feasible for RA control 5
• Antipsychotics for acute psychotic symptoms
• Monitor for hyponatremia (can cause seizures in steroid-treated patients) 7

Concurrent Management Considerations

Rheumatoid Arthritis Steroid Management

• Target: Lowest effective dose, ideally <20mg/day prednisone equivalent 8, 6
• Doses >15-20mg/day increase infection risk and metabolic complications 8, 6
• Optimize DMARD therapy (methotrexate as anchor drug) to minimize steroid dependence 9
• Consider steroid-sparing agents if unable to taper below 7.5mg/day 9

Address the Drooling (Sialorrhea)

This symptom is unusual and concerning:

• May indicate bulbar dysfunction if SREAT with brainstem involvement
• Could represent medication side effect or autonomic dysfunction
• Requires neurological examination for cranial nerve deficits
• If persistent after treating primary condition, consider anticholinergics

Common Pitfalls to Avoid

1. Assuming steroid psychosis without checking anti-TPO antibodies - SREAT mimics steroid psychosis but requires opposite treatment 2, 7

2. Delaying treatment while awaiting antibody results - If clinical suspicion for SREAT is high (subacute cognitive decline, myoclonus, seizures in Hashimoto's patient), start methylprednisolone empirically 1, 2

3. Missing concurrent metabolic derangements - Check sodium urgently (hyponatremia can cause confusion/seizures in steroid-treated patients) 7

4. Overlooking stroke - Acute lacunar infarction can occur during high-dose steroid therapy and present with confusion 7

5. Inadequate steroid taper duration for SREAT - Requires prolonged taper (13 weeks typical), not short course 2

Monitoring During Treatment

• Weeks 1-4: Clinical assessment every 1-2 weeks for symptom response
• Laboratory: Repeat anti-TPO antibodies, TSH, metabolic panel
• Cognitive function: Formal assessment if available
• Steroid complications: Blood glucose, blood pressure, bone density planning 10, 6
• RA disease activity: Ensure adequate control while minimizing steroid exposure 9

Prognosis

• SREAT in older adults: 56.8% achieve near-baseline function with treatment 3
• Steroid-induced psychosis: Resolves with dose reduction/discontinuation
• Both conditions are reversible if recognized and treated appropriately 2, 3

The coexistence of Hashimoto's thyroiditis and rheumatoid arthritis increases autoimmune disease burden and shares common molecular pathways involving immune dysregulation 11, making SREAT more likely in this population.